

**Rational Design of Stable Protein
Formulations: Theory and Practice**

Rational Design of Stable Protein Formulations

Theory and Practice

Edited by

John F. Carpenter

and

Mark C. Manning

*University of Colorado Health Sciences Center
Denver, Colorado*

Kluwer Academic/Plenum Publishers
New York, Boston, Dordrecht, London, Moscow

Library of Congress Cataloging-in-Publication Data

Rational design of stable protein formulations: theory and practice/edited by John F. Carpenter, Mark C. Manning.

p. cm. — (Pharmaceutical biotechnology; v. 13)

Includes bibliographical references and index.

ISBN 0-306-46741-0

1. Protein drugs—Stability. 2. Protein engineering. 3.

Drugs—Design. I. Carpenter, John F. II. Manning, Mark C. III. Series.

RS431.P75 R38 2002

615'.19—dc21

2001057997

ISBN: 0-306-46741-0

© 2002 Kluwer Academic/Plenum Publishers, New York
233 Spring Street, New York, N.Y. 10013

<http://www.wkap.nl/>

10 9 8 7 6 5 4 3 2 1

A C.I.P. record for this book is available from the Library of Congress

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Rational Design of Stable Protein Formulations

Theory and Practice

Pharmaceutical Biotechnology

Series Editor: Ronald T. Borchardt
The University of Kansas
Lawrence, Kansas

Recent volumes in this series:

- Volume 7 PHYSICAL METHODS TO CHARACTERIZE
 PHARMACEUTICAL PROTEINS
 Edited by James N. Herron, Win Jiskoot,
 and Daan J. A. Crommelin
- Volume 8 MODELS FOR ASSESSING DRUG ABSORPTION
 AND METABOLISM
 Edited by Ronald T. Borchardt, Philip L. Smith,
 and Glynn Wilson
- Volume 9 FORMULATION, CHARACTERIZATION, AND
 STABILITY OF PROTEIN DRUGS: Case Histories
 Edited by Rodney Pearlman and Y. John Wang
- Volume 10 PROTEIN DELIVERY: Physical Systems
 Edited by Lynda M. Sanders and R. Wayne Hendren
- Volume 11 INTEGRATION OF PHARMACEUTICAL DISCOVERY AND
 DEVELOPMENT: Case Histories
 Edited by Ronald T. Borchardt, Roger M. Freidinger,
 Tomi K. Sawyer, and Philip L. Smith
- Volume 12 MEMBRANE TRANSPORTERS AS DRUG TARGETS
 Edited by Gordon L. Amidon and Wolfgang Sadée
- Volume 13 RATIONAL DESIGN OF STABLE PROTEIN
 FORMULATIONS: Theory and Practice
 Edited by John F. Carpenter and Mark C. Manning
- Volume 14 DEVELOPMENT AND MANUFACTURE OF PROTEIN
 PHARMACEUTICALS
 Edited by Steven L. Nail and Michael J. Akers

A Chronological Listing of Volumes in this series appears at the back of this volume

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Contributors

Tsutomu Arakawa • Alliance Protein Laboratories, Thousand Oaks, California 91360

John Carpenter • Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262

Byeong S. Chang • Department of Pharmaceutics and Drug Delivery, Amgen, Inc., Thousand Oaks, California 90132

William Garzon-Rodriguez • Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262

Susan Hershenson • Department of Pharmaceutics and Drug Delivery, Amgen, Inc., Thousand Oaks, California 90132

Bert Ho • Tularik Corporation, S. San Francisco, California 94080

LaToya S. Jones • Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262

Brent S. Kendrick • Amgen, Inc., Boulder, Colorado 80301

Geoffrey Lee • Department of Pharmaceutical Technology, Friedrich-Alexander University, Erlangen, Germany

Tiansheng Li • Amgen, Inc., Thousand Oaks, California 90132

Mark Manning • Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262

Jeffrey D. Meyer • Center for Pharmaceutical Biotechnology, Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262

Linda O. Narhi • Amgen, Inc., Thousand Oaks, California 90132

Rajiv Nayar • HTD Biosystems, Hercules, California 94547

Theodore W. Randolph • Center for Pharmaceutical Biotechnology, Department of Chemical Engineering, University of Colorado, Boulder, Colorado 80503

Preface to the Series

A major challenge confronting pharmaceutical scientists in the future will be to design successful dosage forms for the next generation of drugs. Many of these drugs will be complex polymers of amino acids (e.g., peptides, proteins), nucleosides (e.g., antisense molecules), carbohydrates (e.g., polysaccharides), or complex lipids.

Through rational drug design, synthetic medicinal chemists are preparing very potent and very specific peptides and antisense drug candidates. These molecules are being developed with molecular characteristics that permit optimal interaction with the specific macromolecules (e.g., receptors, enzymes, RNA, DNA) that mediate their therapeutic effects. Rational drug design does not necessarily mean rational drug delivery, however, which strives to incorporate into a molecule the molecular properties necessary for optimal transfer between the point of administration and the pharmacological target site in the body.

Like rational drug design, molecular biology is having a significant impact on the pharmaceutical industry. For the first time, it is possible to produce large quantities of highly pure proteins, polysaccharides, and lipids for possible pharmaceutical applications. Like peptides and antisense molecules, the design of successful dosage forms for these complex biotechnology products represents a major challenge to pharmaceutical scientists.

Development of an acceptable drug dosage form is a complex process requiring strong interactions between scientists from many different divisions in a pharmaceutical company, including discovery, development, and manufacturing. The series editor, the editors of the individual volumes, and the publisher hope that this new series will be particularly helpful to scientists in the development areas of a pharmaceutical company, (e.g., drug metabolism, toxicology, pharmacokinetics and pharmacodynamics, drug delivery, preformulation, formulation, and physical and analytical chemistry). In addition, we hope this series

will help to build bridges between the development scientists and scientists in discovery (e.g., medicinal chemistry, pharmacology, immunology, cell biology, molecular biology) and in manufacturing (e.g., process chemistry, engineering). The design of successful dosage forms for the next generation of drugs will require not only a high level of expertise by individual scientists, but also a high degree of interaction between scientists in these different divisions of a pharmaceutical company.

Finally, everyone involved with this series hopes that these volumes will also be useful to the educators who are training the next generation of pharmaceutical scientists. In addition to having a high level of expertise in their respective disciplines, these young scientists will need to have the scientific skills necessary to communicate with their peers in other scientific disciplines.

RONALD T. BORCHARDT
Series Editor

Preface

The need to improve drug development approaches has become even more important in this post-genomic era. The number of drug candidates is escalating in most companies. As a result, every aspect of drug development must become more efficient and accurate. This volume is intended as a treatise on the state-of-the-art in formulation and stabilization of protein pharmaceuticals. As we approach the twentieth anniversary of the introduction of a recombinant protein therapeutic agent (human insulin, 1982), it is timely to summarize the advances made in formulation of proteins. The earlier two volumes in this series dedicated to protein stability continue to be widely used in the industry as reference works. However, this volume is intended to move beyond that work. Rather than providing a traditional description of mechanisms and concepts, this volume is intended to be more practical, trying to emphasize that our understanding of protein stability has evolved to the point where rational design of some formulations can be achieved. Furthermore, two of the chapters introduce new stabilization and formulation strategies that may provide future directions in this field. We believe the modern practitioner of protein formulation should find this volume of use, whether they are experts or neophytes.

The first chapter, authored by Byeong Chang and Susan Hershenson from Amgen, is entitled "Practical Approaches to Protein Formulation Development". This chapter will not only talk about modes of decomposition of protein but provides readable and practical guide on how to turn theoretical insight into a manufacturable, stable product. It also provides the reader with insight into the practical constraints placed on scientists actually doing formulation development.

Chapter 2, by Tsutomu Arakawa, Tiansheng Li, and Linda Nahri, introduces the reader to critical issues of refolding proteins produced in *E. coli*. For someone new to this field, the authors provide a number of experimental details and clearly describe the current approaches towards obtaining high yields of

native proteins from inclusion bodies. By providing such great detail, the reader can quickly identify the prior work that is most relevant to their current needs.

The third chapter, entitled "Physical Stabilization of Proteins in Aqueous Solution", is written by Brent Kendrick, Tiansheng Li, and Byeong Chang. A fundamental principle in protein stabilization is the ability of additives (excipients) to alter the thermodynamic stability of a protein's structure. These thermodynamic effects arise from preferential binding or exclusion of the additive from the surface of the protein, as first described by Serge Timasheff and co-workers. This chapter provides a detailed tutorial on the theory and then proceeds to outline the impact of these effects on the stability of protein pharmaceuticals. These effects are important in development of liquid formulations, stabilization during lyophilization, and protein aggregation.

The next chapter introduces an emerging appreciation that susceptibility to chemical degradation can be modulated by the conformation of the protein (or even peptide). Entitled "Effects of Conformation on the Chemical Stability of Pharmaceutically Relevant Peptides", by Jeffrey Meyer, Bert Ho, and Mark Manning, summarizes the data in the literature that indicate it is possible to minimize chemical degradation by altering conformation. One possible method for accomplishing this would be to add preferentially excluded solutes (as described in chapter 3) to compact the structure of the protein. This has worked to diminish aggregation and is now being shown to be effective at slowing chemical decomposition as well. Altogether, this approach could provide a new strategy for developing liquid formulations of peptides and proteins.

The one area where our understanding of protein behavior has truly advanced is for freeze-dried formulations. The authors of the next chapter, John Carpenter, Byeong Chang, William Garzon-Rodriguez, and Theodore Randolph, provide an overview of what is required to produce a stable formulation of a protein in a lyophilized cake. Not only do the authors provide an excellent summary of the advances that have been made in understanding the behavior of proteins during freeze-drying, they translate that theoretical insight into a step-by-step guide to producing reasonable, practical formulations that should work for most any protein pharmaceutical.

Chapter 6, authored by Geoff Lee, is an overview of the development of spray-dried protein formulations. This process has received a large amount of attention in recent years, and this chapter describes the process, the equipment, and formulation concerns that need to be addressed if one is to use this approach to make dried powders of proteins that will retain native structure and activity.

Chapter 7 focuses on the role of surfactants in stabilizing proteins. Over the past few years, an increasing number of mechanisms by which surfactants can stabilize proteins have been described. This chapter, by Theodore Randolph and LaToya Jones, provides an overview about the behavior of this important class of excipients. Even the most experienced formulation scientist probably

does not appreciate all of the subtleties of protein-surfactant interactions. Understanding these mechanisms will allow for a more rational choice of which surfactant (if any) to use and at what concentration.

The last chapter is intended to spur discussion about new strategies to designing formulations of protein pharmaceuticals. Although the drug discovery field has been revolutionized by combinatorial libraries, high throughput screening, and genomics, similar high throughput approaches have not received much attention in the drug development field. This chapter, written by Rajiv Nayar and Mark Manning, will hopefully cause workers in this field to examine their current approaches and seek to find more efficient modes of operation. It is the authors' belief that the demand to develop more products simultaneously with less material and in less time will ultimately transform the field of formulation science.

For anyone who wishes to learn the state-of-the-art in formulating and stabilizing protein drug products, this book should provide information on all aspects, covering not only what is well established, but also where we are and where we are going. The goal is to ensure that the reader has the mechanistic understanding of how proteins degrade and can be stabilized rationally, and then provide practical advice on how to translate that knowledge into action.

JOHN CARPENTER
MARK C. MANNING

Contents

Chapter 1

Practical Approaches to Protein Formulation Development

Byeong S. Chang and Susan Hersenson

Introduction	1
Preparation for Formulation Development	3
Resource Requirements for Formulation Development	3
Useful Information for Designing Formulations	4
Preformulation Development	4
Characterization of Protein Pharmaceuticals	5
Accelerated Stability Studies	5
Development of Analytical Methods	6
Evaluation of the Significance of Problems	7
Formulation Development	10
Formulation Options for Protein Pharmaceuticals	10
Typical Protein Stability Problems: Causes and Solutions	13
Optimization of Formulation Variables	13
Necessary Studies for Formulation Development	15
Strategies to Overcome Difficult Formulation Problems	17
Formulation in Commercial Product Development	18
Critical Formulation Decisions During Pharmaceutical Development	18
Formulation for Early Preclinical and Clinical Studies	19
Commercial Formulation	19
Regulatory Issues in Formulation Development	20

Appendix: List of Regulatory Documents	22
References	23

Chapter 2

Recombinant Production of Native Proteins from *Escherichia coli*

Tsutomu Arakawa, Tiansheng Li, and Linda O. Narhi

Introduction	27
Distribution of Expressed Proteins	28
Cell Washing and Lysis	32
Purification of Soluble, Folded Proteins	34
Purification and Refolding of Soluble, Misfolded Proteins	35
Purification and Refolding of Proteins from Inclusion Bodies	36
Washing and Solubilization of Inclusion Bodies	36
Purification of Expressed Proteins from Inclusion Bodies	36
Refolding Mechanism	38
Disulfide Bond Formation	41
Removal of Denaturant	41
Effects of Tag Sequences	44
Effects of Excipients	44
Response Surface Methodology	47
High Pressure Disaggregation and Refolding	48
Methods to Analyze Folded Structures	48
Bioactivity	49
Binding to Receptors	49
Disulfide Bond Analysis	50
Spectroscopy	50
Conformational Stability	51
Limited Proteolysis	51
References	51

Chapter 3

Physical Stabilization of Proteins in Aqueous Solution

Brent S. Kendrick, Tiansheng Li, and Byeong S. Chang

Introduction	61
Overview of Physical Stability	62

Thermodynamic Control of Protein Stability	62
Kinetic Control of Protein Stability	63
Interactions of Excipients with Proteins	65
Preferentially Excluded Cosolvents	66
Buffers/Salts	67
Specific Binding of Ligands	68
Protein Self-Stabilization	69
Physical Factors Affecting Protein Stability	70
Temperature	70
Freeze-Thawing	71
Agitation and Exposure to Denaturing Interfaces	71
Pressure	72
Conclusions	73
Appendix: Derivation of the Wyman Linkage Function and Application to the Timasheff Preferential Exclusion Mechanism	73
References	78

Chapter 4

Effects of Conformation on the Chemical Stability of Pharmaceutically Relevant Polypeptides

Jeffrey D. Meyer, Bert Ho, and Mark C. Manning

Introduction	85
Relationship Between Structure and Deamidation Rates	86
Primary Structure Effects	87
Secondary Structure Effects	89
Tertiary Structure Effects	91
Summary of Structure Effects on Deamidation	92
Role of Structure in Protein Oxidation	92
Types of Oxidation Processes	93
Effects of Oxidation of Surface and Buried Methionines on Protein Structure	95
Limiting Solvent Accessibility of Residues	96
Conformational Control of Oxidation in Aqueous Solution	97
Structural Control of Oxidation in Lyophilized Products	99
Summary of Structural Control of Oxidation	100
Summary	101
References	101

Chapter 5

**Rational Design of Stable Lyophilized Protein Formulations:
Theory and Practice***John F. Carpenter, Beyong S. Chang, William Garzon-Rodriguez, and
Theodore W. Randolph*

Introduction	109
Minimal Criteria for a Successful Lyophilized Formulation	111
Inhibition of Lyophilization-Induced Protein Unfolding	112
Storage at Temperatures Below Formulation Glass Transition Temperature	113
The Water Content is Relatively Low	114
A Strong, Elegant Cake Structure is Obtained	114
Steps Taken to Minimize Specific Routes of Protein Chemical Degradation	116
Rational Design of Stable Lyophilized Formulations	117
Choice of Buffer	118
Specific Ligands/pH that Optimizes Thermodynamic Stability of Protein	119
Trehalose or Sucrose to Inhibit Protein Unfolding and Provide Glassy Matrix	120
Bulking Agent (e.g., Mannitol, Glycine or Hydroxyethyl Starch)	126
Nonionic Surfactant to Inhibit Aggregation.	127
Acknowledgments	127
References	127

Chapter 6

Spray-Drying of Proteins*Geoffrey Lee*

Introduction: Why Spray-Dry a Protein?	135
Developments in the Last 10 Years	136
The Practice of Spray-Drying Proteins	139
Type of Equipment	139
Spray-Drying Conditions	140
Influence of Formulation	147
Pure Proteins	147
Formulated Systems	149
Use of Added Surface Active Substances	151

Concluding Remarks	156
References	156

Chapter 7

Surfactant-Protein Interactions

Theodore W. Randolph and LaToya S. Jones

Introduction	159
Proteins and Surfactants at Surfaces	161
Protein-Surfactant Interactions in Solution	166
Surfactant Effects on Protein Assembly State	167
Surfactant Effects on Proteins During Freezing, Freeze-Drying and Reconstitution	169
Enzymatic Degradation of Non-Ionic Surfactants	170
Recommendations for Protein Formulation	170
References	171

Chapter 8

High Throughput Formulation: Strategies for Rapid Development of Stable Protein Products

Rajiv Nayar and Mark C. Manning

Introduction	177
Overall Structure of the HTF Approach	179
Role of an Established Decision Tree for Formulation Design	181
Constraints on a Pharmaceutically Acceptable Protein Formulation	182
Proper Choice of Dosage Form	183
Preformulation Studies	185
Proper Choice of Excipients	186
Estimates of Resources Needed for Formulation Development	188
Use of Software and Databases to Assist in the HTF Process	189
Essential Analytical Methods	191
Stability Protocols	193
Unified Strategy for HTF	194
References	195
Index	199